Opexa Therapeutics

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS). The Company’s lead therapy, Tovaxin®, a personalized cellular immunotherapy treatment, is in late stage clinical development targeting both Secondary Progressive and Relapsing Remitting MS.

Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

Neil Warma

(281) 719-3437
nwarma@opexatherapeutics.com
Visit Opexa Therapeutics